proliferation and formation of multinucleated giant cells (MNGC; Langhans-type cells) from monocytemacrophages during granulomatous reaction. The proliferation of monocyte-macrophages into MNGC has been observed in a number of chronic infectious and inflammatory diseases caused by mycobacterium and fungi, as well as in other diseases, including hypersensitivity pneumonitis, HIV infection and sarcoidosis (19) (20) . These coincide with the diseases that respond well to thalidomide treatment. In the improved tissue, extensive T-cell recruitment was observed, followed by the disappearance of MNGC and the destruction of granulomas (16) .
Therefore, we hypothesized that thalidomide might exert its anti-inflammatory actions by modulating both cytokine-induced maturation and the differentiation of monocyte-macrophages into MNGC sarcoidal granulomatous lesions. We tested this hypothesis by studying the effects of thalidomide on the macrophage differentiation system. Macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and TNF-a were possible mediators inducing macrophage differentiation and prolonging their survival effectively in vitro (21) (22) (23) (24) (25) (26) (27) .
MATERIALS AND METHODS

Reagents
RPMI-1640 and PBS were from GIBCO (Grand Island, NY). Other chemical compounds including thalidomide were purchased from Sigma (St Louis, MO), and human cytokines (M-CSF, GM-CSF, IL-4 and TNF-a) and the control rabbit antibody from Wako Pure Chemical Industries (Osaka, Japan). Anti-human TNF-a (neutralizing) antibody and the antibody against Ecadherin were purchased from R&D Systems (Abingdon, United Kingdom). Thalidomide analogue (lenalidomide) was obtained from Celgene (Warren, NJ).
Monocyte separation and cell cultures
Peripheral blood mononuclear cells (PBMCs) were isolated by Histo-Paque (Sigma) density gradient centrifugation. Human monocytes were isolated from healthy adult volunteers by negative selection with mAbcoated immunologic magnetic beads and a cell sorter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) after centrifugation. Purity was assessed by the detection of reactive oxygen species with a fluorescence probe [hydroxyphenyl fluorescein (28) ] stimulated with 10 ng/ ml PMA and by saturation with anti-CDl4 MAb (10M2: Immunotech; Marseille, France) using a flow cytometer, and both were more than 95%. Monocyte-macrophages were cultured at 3TC and a 5% CO 2 atmosphere in condition medium consisting of RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 50 U/mL penicillin, 50 ug/ml, streptomycin, and 10 mM HEPES at 2 x 10 6 cells12mLlwellin 12-well tissue culture plates (Sumitomo Bakelite, Tokyo, Japan) with several cytokines. All culturing procedures were performed under sterile conditions, and each experiment was performed at least in triplicate. The cells were maintained for 4 days, at which time the medium was replaced with the same volume of medium supplemented with various cytokines.
Cell staining and evaluation ofMNGC formation
Culture plates were gently rinsed twice with PBS and dried well, and the cells were stained with May-Grunwald-Giemsa stain (Merck Ltd, Darmstadt, Germany). Digital pictures at low power (20 x objectives) were taken with a microscope (Keyence, Osaka, Japan) under LV light for the quantification of MNGC. Photomicrographic data are representative of a minimum of three separate experiments using monocytes from different blood donors. The number of visible nuclei within MNGC was expressed as the mean percentage of total nuclei counted in four representative microscopic fields.
RNA interference
Small interfering RNAs (siRNAs) specific to human TRAP1, TNFRSFIA, TNFRSFIB were purchased from Invitrogen (Carlsbad, CA). The non-targeting siRNAs for the human genome was used as control. siRNA transfection was performed with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. Isolated human monocytes were transfected with 50 nM siRNA for 48 h, and incubated with cytokines for 14 days.
Supernatant collection and cytokine analysis
After 7 days' incubation without a change in culture medium, supernatants were collected and centrifuged at 2,000 rpm to remove particulate debris, then were stored at -30·C. IL-l~was measured by a two-site-directed enzyme-linked immunosorbent assay (ELISA) with an exclusion limit of 10 pg/ml (Pierce Biotechnology, Rockford,IL). TNF-a was assessed by a specific ELISA, with a sensitivity of 0.5 pg/ml (Pierce Biotechnology). IL-IO was also measured by an ELISA with a sensitivity of 2.0 pg/ml. IFN-y was measured by an enzyme immunoassay (EIA) with a sensitivity of 0.1 pglml.
Statistical analysis
Scheffe's test for all pairs was used to compare groups with and without thalidomide. These data are shown as means ± SD, and were analyzed using statistical software for Excel (Atoms, Tokyo, Japan). Results with p values less than 0.05 were considered statistically significant.
RESULTS
Monocytes cultured in M-CSF, IL-4 and their combination
Exposure of peripheral blood monocytes to IL-4 (20 ng/ml) + M-CSF (10 ng/ml) for 14 days led to their morphologic change into fibrous cells and their assembly into Langhans-type cells. The experiments were highly reproducible. The May-Griinwald-Giemsa staining on the well culture plate appeared distinct when incubated with different combinations of cytokines. M-CSF by itself induced cellular survival of monocytes and their differentiation into foamy macrophages, and IL-4 by itself induced large fibrous macrophages ( Fig. Ia, b ). Assembling masses (large multinucleated giant cells; Langhanstype cells) from macrophages were observed more abundantly in the co-incubation with IL-4 and M-CSF ( Fig Ic) . Expression ofcell adhesion molecules, including E-cadherin, was also increased during the incubation with both cytokines (Fig. l d) .
Effect of thalidomide on monocyte-macrophage differentiation
As shown in Fig. 2a , thalidomide, at a low but pharmacologically relevant concentration of 5-10 ug/ml, significantly inhibited the formation offoamy (Fig. 2a ). Inhibition of MNGC formation and reduction in the size ofmacrophages by thalidomide. A) 0.1% DMSO and cytokines (control); B) 5 ug/ml: thalidomide; C) 10 ug/ml. thalidomide; D) 50 ug/ml: thalidomide. The number of visible nuclei within MNGC (Langhans-type cells) expressed as a mean percentage of total nuclei counted in four representative microscopic fields (Fig. 2b) . Results are expressed as means ± SD (*p<0.05 compared to without thalidomide, **p<0.01 compared to without thalidomide and p<0.05 compared to LUug/ml thalidomide) from three independent experiments. macrophages and MNGC for 7-14 days, and reduced the percentage of visible nuclei within MNGC from 50% to 20% ( Fig. 2b; 10 ug/ml., 60% inhibition). Meanwhile, 50 ug/ml thalidomide achieved 90% inhibition. Thalidomide is poorly soluble and requires, an intermediate stock dilution in DMSO (285 mg/ml: 1 mM), which was stored at -30°C. DMSO is known as an agent to induce differentiation and morphological changes in monocytic leukemia cell lines (29) , however, the final concentration of DMSO was lower than 0.02%; it had little effect on the pH of culture media in our experiment and little effect on monocyte-macrophage differentiation at the concentration of 0.02%, as previously reported (30) . Again, thalidomide led to a significant reduction in the numbers of MNGC in our experiment. Thalidomide's effect was dose-dependent, and the viability of the cells was unchanged when tested by trypan blue exclusion. In addition, the expression levels of E-cadherin was decreased under the incubation with thalidomide (data not shown).
Effects of M-CSF, IL-4 and/or thalidomide on cytokine release from incubated monocytes
The production of cytokines (monokines) was evaluated in the supernatant of culture medium for 7 days. In the three subjects tested, the treatment with M-CSF and IL-4 together induced significant production of TNF-a, IFN-y and IL-l~, while IL-10 was not detected (Table I ). In the presence of thalidomide, the production of TNF-a and IFN-y was inhibited, depending on the concentration. Meanwhile, the production of IL-l~was little affected by the presence of thalidomide.
Effects of neutralizing TNF-o. antibody and RNA interference of TNF receptor on MNGC formation from incubated monocytes
Peripheral blood monocytes were incubated with IL-4 (20 nglml) and M-CSF (10 ng/ml) for 14 days. As shown in Fig. 3 , the addition ofneutralizing TNFa antibody (50 ng/ml, R&D Systems, Minneapolis, MN; MAB2101) weakened the effect of IL-4 + M-CSF and reduced the formation of MNGC. Furthermore, small interfering RNAs (siRNAs) specific to human TRAP 1 and TNFRSF 1A reduced the formation of MNGC but siRNA specific to TNFRSFIB had little effect (data not shown).
DISCUSSION
Thalidomide has been showing significant promise in the treatment of various immunologic disorders. First thalidomide can selectively inhibit TNF-a production by variously stimulated macrophages (17) (18) 31) . Thalidomide has also been shown to modulate the production of chemokines and several cytokines besides TNF, such as IL-l~, IL-4 and anti-inflammatory IL-IO from microglia and lymphocytes (32) (33) . These immunoregulatory activities of thalidomide might be relevant to its efficacy against pathophysiological conditions in sarcoidosis, tuberculosis and leprosy (chronic granulomatous disorders: granulomatosis).
These diseases are specially characterized by the formation of granuloma and multinucleated giant cells in their histopathology. Their granulomas consist of non-differentiated macrophages and epithelioid cells, with Langhans-type multinucleated giant cells and scattered lymphocytes (16) . Sarcoidosis is a multi-systemic disease of unknown etiology, for which thalidomide has been reported to be especially beneficial (14) (15) (16) . It is noteworthy that, as Oliver et al. reported, thalidomide treatment in sarcoidosis decreases the size of granuloma in the lesions, reduces epidermal thickness, activates macrophage responses, recruits T-cells into the granulomas and finally changes the histological appearance of granulomas (16) . Meanwhile, the precise pharmacological actions underlying thalidomide's effects have remained uncertain. The activation and differentiation of macrophages may play pivotal roles in the granuloma formation process in these diseases; elucidation of the regulatory mechanisms of this process is likely to help resolve the puzzle of the clinical efficacy of thalidomide.
In the present study, we used a pure population of peripheral blood monocytes to investigate their differentiation into mature macrophages and the formation of Langhans-type cells in vitro. Our experimental approach permitted the reproduction of cellular changes observed in previous studies (19) (20) 34) during the development of granulomas, as well as the formation of MNGC. We demonstrate that MNGC can be generated from peripheral blood monocytes in the absence of other cell populations, and that both IL-4 and M-CSF can provide a sufficient stimulus for the induction of such differentiation pathways. Macrophages effectively differentiate into MNGC with the increased levels ofE-cadherin.
Notably, we also demonstrated that thalidomide can inhibit MNGC formation in a dose-dependent manner. Mutinucleated cells and extra-large foamy cells were not observed in the thalidomide-containing cultures, and the cells were smaller. Interestingly, MNGC formation was inhibited by the presence of a TNF-a-neutralizing antibody or interference of TNF-a receptor with siRNA. Thalidomide was a potent inhibitor of NF-KB activation induced by lipopolysaccharide and several cytokines (35) . These data suggest that the initial roles of NF-KB activation and autocrinal TNF-a production might be involved in this inhibitory action of thalidomide. Thalidomide concentrations used in the study (5-10 ug/ml) are attainable plasma concentrations obtained after administration of oral doses of 200-400 mg thalidomide. We performed some experiments with thalidomide analogue lenalidomide. We found the same efficacy of lenalidomide at the same concentrations compared to thalidomide. The potency was not different between these drugs. In our experiment, IFN-y and IL-l~were also detected in the macrophage-cultured supernatant, but only in small quantities: and these cytokine were reported to have less effect on monocyte-macrophage differentiation compared to IL-4, M-CSF, GM-CSF and TNF-a. Thalidomide can induce apoptosis in human monocytes (36) . However, definitive monocyte cell death and the elevated caspase activity were not observed in our experiments (data not shown), our results may not be easily attributed to reduced cell viability.
Oliver et al. (16) reported that thalidomide treatment of sarcoidosis patients resulted in systemic and local immune activation associated with improvement ofskin diseases and clinical symptoms, and they also found pathological improvement (depletion of multinucleated giant cells in the late phase), although an increased giant cell formation was observed in the initial stage with increased concentrations of plasma TNF-a in their patients. In this study we demonstrate that similar findings are reproducible in vitro. Interestingly, BCG vaccination is known to be associated with the onset ofjuvenile sarcoidosis (37) . Although the pathogenesis remains to be elucidated, a potential risk of inducing the production of proinflammatory cytokines (such as TNF-a, IFN-y) that affect on formation of MNGC may be a trigger to systemic granulomatosis. This is the first report on the effect ofthalidomide on multinucleated giant cell (Langhans-type cell) formation from human peripheral blood monocyte-macrophages in vitro. Our results are consistent with previous in vivo findings and strongly support the clinical efficacy of thalidomide to treat granulomatous diseases (granulomatosis) despite its serious teratogenic potential in women of childbearing age. Based on our findings, we believe that thalidomide may be an alternative treatment step for chronic inflammatory disorders (granulomatosis) through the inhibition ofMNGC formation.
